Galvanize raises $130M Series D for pulsed-field expansion
What's the deal? Galvanize Therapeutics has closed an oversubscribed $130 million Series D led by HealthQuest CapitalDealroom has a profile for this one. Try Dealroom →, a growth equity firm focused on commercial-stage healthcare companies. The Redwood City, California startup develops pulsed electric field (PEF) ablation technology for oncology and chronic disease.
Who's in: Olympus Innovation VenturesDealroom has a profile for this one. Try Dealroom → and Braidwell LPDealroom has a profile for this one. Try Dealroom → joined as new investors. Existing backers Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge GroupDealroom has a profile for this one. Try Dealroom →, Perceptive Advisors, Janus Henderson Investors, Longaeva PartnersDealroom has a profile for this one. Try Dealroom →, Fidelity Management & Research Company, and T. Rowe Price Associates also participated.
Why now? The round follows an oversubscribed $100 million Series C in September 2025, extending a steady financing run as Galvanize shifts from development toward commercialization. The company won FDA 510(k) clearance for its Aliya EX generator in May 2026 and logged its first commercial procedures that August.
What's the endgame? Galvanize aims to become the global leader in PEF technology, starting with chronic bronchitis symptoms, cardiac arrhythmias, and solid tumors. Proceeds will fund commercial expansion of Aliya, clinical evidence generation, its RheOx therapy for chronic bronchitis, and next-generation PEF platforms.
"This financing marks an important inflection point for Galvanize," said chief executive officer Doug Godshall. The company says it has surpassed 4,000 procedures and enrolled more than 300 patients in its PROPEL registry.
What could go wrong? Adoption remains early, and the FDA clearance covers surgical ablation of soft tissue — not a disease-specific indication. The cancer and chronic-bronchitis applications still depend on clinical evidence and, where relevant, further regulatory progress.
The signal: At $130 million, the round sits above the 91st percentile for US Series D health rounds, a mark of continued investor conviction in the PEF platform. But the raise also underscores that proof of commercial scale and broader uptake remain to be demonstrated.
Read more: finance.yahoo.com
Image credit: Galvanize Therapeutics